Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- Check6 days agoChange DetectedNew version entries were added: Revision v3.4.3 on 2026-03-10 and 2026-03-07. The previous Revision v3.4.2 was removed on 2026-03-03 and 2026-02-28.SummaryDifference0.1%

- Check13 days agoChange DetectedNew update dates (2026-03-03 and 2026-02-28) were added to the study record history, and older update dates (2026-02-24 and 2026-02-21) were removed.SummaryDifference0.1%

- Check20 days agoChange DetectedUpdates posted on 2026-02-21 and 2026-02-24 were added, and updates dated 2026-02-14 and 2026-02-17 were removed.SummaryDifference0.1%

- Check27 days agoChange DetectedNew study record updates dated 2026-02-14 and 2026-02-17 were added; updates dated 2026-02-07 and 2026-02-10 were removed.SummaryDifference0.1%

- Check34 days agoChange DetectedPage updates include revision v3.4.2 with dates 2026-02-10 and 2026-02-07, and the earlier funding lapse notice has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedThe page now includes a government funding lapse notice banner and an updated revision note (v3.4.1) with new dates 2026-02-03 and 2026-01-31; earlier dates 2026-01-27 and 2026-01-24 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.